The #1 prescribed NOAC across
the continuum of care*1
The patients they studied are the ones I see.
AMONG NOACs:
Most real-world experience: more than 2.5 million patients prescribed
in the US.2
Most safety data generated in clinical trials in patients
studied with high risk of thrombotic events.†3-16
Most affordable: the lowest average
out-of-pocket cost.17
Not intended to be a comparison of safety
or efficacy outcomes.
*Hospital, Long-Term Care, Retail.
†
Based on the following: CHADS2 scores 3-6 in ROCKET AF (N=12,402), ARISTOTLE
(N=5502), ENGAGE-AF (N=~11,200), and RE-LY (N=5882); risk factors of DVT, PE,
DVT/PE, cancer, elderly, previous VTE, provoked VTE, unprovoked VTE, and recent
trauma or surgery in EINSTEIN pooled analysis (N=8281), AMPLIFY (N=5395),
Hokusai-VTE (N=8240), and RE-COVER I and II (N=5107).
IMPORTANT SAFETY INFORMATIO